Joseph Patti
Director/Board Member chez ARMATA PHARMACEUTICALS, INC.
Fortune : - $ au 31/03/2024
Profil
Joseph M.
Patti is the founder of Inhibitex LLC, which was founded in 1994.
He held the title of Senior Vice President-Research & Development from 2007 to 2012.
Dr. Patti's current jobs include being an Independent Director at Armata Pharmaceuticals, Inc. since 2019, a Director at ECM Biosurgery, Inc. since 2019, and the President of JP Biotech Advisors, Inc. since 2018.
Dr. Patti's former jobs include being the President, CEO & Executive Director of Aviragen Therapeutics, Inc. from 2014 to 2018, the President & Chief Executive Officer of Vaxart, Inc., the President, Chief Executive Officer & Director of Agilvax, Inc. from 2019 to 2021, the President, CEO & Executive Director of Evecxia, Inc. from 2022 to 2023, and a Director at SciStem, Inc. from 2012 to 2015.
He also served as an Assistant Professor at Texas A&M University from 1994 to 1998 and at the Institute of Biosciences & Technology from 1994 to 1998.
Dr. Patti's education includes an undergraduate degree from the University of Pittsburgh, a doctorate degree from The University of Alabama at Birmingham, and a graduate degree from The University of Miami Leonard M.
Miller School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Joseph Patti
| Sociétés | Poste | Début |
|---|---|---|
| ARMATA PHARMACEUTICALS, INC. | Director/Board Member | 09/05/2019 |
ECM Biosurgery, Inc.
 ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | Director/Board Member | 01/03/2019 |
| JP Biotech Advisors, Inc. | President | 01/02/2018 |
Anciens postes connus de Joseph Patti
| Sociétés | Poste | Fin |
|---|---|---|
Evecxia, Inc.
 Evecxia, Inc. Miscellaneous Commercial ServicesCommercial Services Evecxia, Inc. is engaged in biotechnology services. The company was founded by Jacob Jacobsen and Marc Caron and is headquartered in Research Triangle Park, NC. | Chief Executive Officer | 14/09/2023 |
Agilvax, Inc.
 Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | Chief Executive Officer | 01/07/2021 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Chief Executive Officer | 01/02/2018 |
SciStem, Inc.
 SciStem, Inc. Pharmaceuticals: MajorHealth Technology SciStem, Inc. operated as an early stage regenerative medicine company developed novel cell and cell-based gene therapies for bone healing and musculoskeletal indications in people and pets. The company was headquartered in Athens, GA. | Director/Board Member | 01/01/2015 |
Inhibitex LLC
 Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Founder | 01/02/2012 |
Formation de Joseph Patti
| University of Pittsburgh | Undergraduate Degree |
| The University of Alabama at Birmingham | Doctorate Degree |
| The University of Miami Leonard M. Miller School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VAXART, INC. | Health Technology |
| ARMATA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Health Technology |
Agilvax, Inc.
Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | Health Technology |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
SciStem, Inc.
SciStem, Inc. Pharmaceuticals: MajorHealth Technology SciStem, Inc. operated as an early stage regenerative medicine company developed novel cell and cell-based gene therapies for bone healing and musculoskeletal indications in people and pets. The company was headquartered in Athens, GA. | Health Technology |
Evecxia, Inc.
Evecxia, Inc. Miscellaneous Commercial ServicesCommercial Services Evecxia, Inc. is engaged in biotechnology services. The company was founded by Jacob Jacobsen and Marc Caron and is headquartered in Research Triangle Park, NC. | Commercial Services |
| JP Biotech Advisors, Inc. | |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | Technology Services |
